No other clinical or research grade technology can provide passive measures of bradykinesia – establishing the PKG as an essential objective measure of bradykinesia in clinical decision-making.
2. The consensus findings establish the importance of the PKG’s status as a clinically-validated medical grade technology cleared by multiple regulatory bodies with CPT codes supporting clinical use.
The PKG system is cleared to market for clinical use in 17 countries, including FDA clearance for the US and CE marking for Europe.
3. Early clinical evidence and expert opinion suggest a role for the PKG in influencing and enhancing clinical decision-making.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
In several routine clinical scenarios, use of the PKG can provide clinically meaningful data to aid clinical decision-making.
Early clinical experience and expert opinion suggest that utilization of continuous objective measurement technologies such as the PKG have the potential to improve medical care in people with Parkinson’s disease.
To date, more than 30,000 patient PKG reports have been supplied to tailor therapy and improve management for Parkinson’s patients. More than 3,000,000 recording hours have been provided to 200 Parkinson’s specialist clinics across the world.
John Schellhorn, CEO of Global Kinetics Corporation, said, “Global Kinetics is proud to announce this latest achievement in its commercial trajectory – and more importantly in our mission to make a meaningful difference for all people with Parkinson’s. While there is much interest and dialogue about wearable technologies in Parkinson’s, two international panels of experts have recognized the value of the PKG in routine care. These publications position the PKG as enhancing the management of Parkinson’s disease and differentiate it from other research and investigatory tools. These studies, combined with the CPT III codes which will become effective January 1, 2019, position the PKG as a viable tool to objectively measure key Parkinson’s symptoms. We are excited to provide a product which will assist clinicians in optimizing therapy for their PD patients.”
About Global Kinetics Pty Ltd.
Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialise its lead product, the Personal KinetiGraph™ (PKG™), also known as the Parkinson’s KinetiGraph™ outside the USA. Developed in conjunction with the world-renowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, the PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s. To date, Global Kinetics has supported clinical decisions for doctors who treat patients with Parkinson’s disease across 17 countries with more than 3,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis, MN, and Portsmouth, NH, USA.
Back to HCB News
